WebSep 9, 2024 · Breast cancer is the most common malignancy diagnosed in women. Traditionally, radical surgical resection was the cornerstone of breast cancer management, with limited exceptions. In recent times, our enhanced appreciation of the biomolecular characteristics of breast cancer has transformed the treatment paradigm to include … WebDec 1, 2024 · Purpose: Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard …
RxPONDER Results Published in NEJM SWOG
WebJul 5, 2024 · CC BY 4.0. UPDATE: On August 5, 2024, the Food and Drug Administration (FDA) approved trastuzumab deruxtecan (Enhertu) for the treatment of HER2-low breast cancers that can’t be removed surgically, … WebDec 9, 2024 · Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast … cleaning sop
Oncology and Hematology : NEJM Journal Watch
WebApr 13, 2024 · The U.S. Preventive Services Task Force (USPSTF) recommends shared decision-making about prostate-specific antigen (PSA) screening for prostate cancer in older men (age range, 55–69; NEJM JW Gen Med Jun 15 2024 and JAMA 2024; 319:1901); the American Urologic Association (AUA) agrees and recommends a screening interval … WebBreast cancer is the most common female malignancy in the USA and the second leading cause of cancer death in women . ... Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. New England Journal of Medicine. 2005; 353 (16):1659–72. WebDec 1, 2024 · The NEJM article is "21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer." The S1007 RxPONDER study was sponsored by the … cleaning sophie the giraffe